ImmunityBio: One Regulatory Win Could Reprice This Biotech Into A Multi-Billion Dollar Story
ImmunityBio (IBRX) just saw the FDA accept an expanded-use sBLA for ANKTIVA + BCG in BCG-unresponsive NMIBC with a PDUFA of 01/06/2027. The stock is trading at roughly $8.20 and a market cap near $8.6B. Positive approval odds and superior trial outcomes relative to incumbents argue for a directional long; material legal risk and high short interest…